90705_Auto_Edited.docx

Can serum immunoglobulin G4 levels and age serve as reliable predictors of relapse in autoimmune pancreatitis?

Song JM *et al*. Serum IgG4 and relapse in AIP

Jun-Min Song, Si-Yu Sun

Abstract

We are writing in response to the paper published in the *World Journal of Gastroenterology* by Zhou *et al*. The authors identified higher serum immunoglobulin (Ig) G4 levels and age over 55 years as independent risk factors for disease relapse. Despite notable strengths, it is crucial to address potential biases. Firstly, the cohort study included 189 patients with autoimmune pancreatitis (AIP) type 1 (with higher IgG4 seropositivity and higher relapse) and 24 with type 2 (with lower IgG4 seropositivity and lower relapse). Consequently, most, if not all, AIP type 2 patients were assigned to the normal group, possibly inflating the association of higher serum IgG4 levels with relapse and potentially exaggerating the association of older age with relapse. Secondly, the authors did not provide sufficient details regarding AIP diagnosis, such as the ratio of definitive *vs* probable cases and the proportion of biopsies. In cases where histological evidence is unavailable or indeterminate, AIP type 2 may be misdiagnosed as definitive type 1, and type 1 may also be misdiagnosed as probable type 2, particularly in cases with normal or mildly elevated serum IgG4 levels. Lastly, in this retrospective study, approximately one-third of the consecutive patients initially collected were excluded for various reasons. Accordingly, the impact of non-random exclusion on relapse outcomes should be carefully considered. In conclusion, the paper by Zhou *et al* offers plausible, though not entirely compelling, evidence suggesting a predictive role of elevated serum IgG4 levels and advanced age in AIP relapse. The foundation for future investigations lies in ensuring a reliable diagnosis and accurate disease subtyping, heavily dependent on obtaining histological specimens. In this regard, endoscopic ultrasound-guided fine-needle biopsy emerges as a pivotal

component of the diagnostic process, contributing to mitigating biases in future explorations of the disease.

Key Words: Autoimmune pancreatitis; Immunoglobulin; Endoscopic ultrasound; Relapse; Age

Song JM, Sun SY. Can serum immunoglobulin G4 levels and age serve as reliable predictors of relapse in autoimmune pancreatitis? *World J Gastroenterol* 2024; In press

Core Tip: This paper assesses the strengths and potential biases of the provided study. Accurate diagnosis and subtyping are crucial for both clinical practice and research. In this context, endoscopic ultrasound-guided fine-needle biopsy emerges as a pivotal component of the diagnostic process, playing a key role in mitigating the introduction of various biases in future investigations of autoimmune pancreatitis.

TO THE EDITOR

We are writing in response to the recent clinical research paper published in the *World Journal of Gastroenterology* by Zhou *et al*[1]. In their study, the authors presented a cohort of 213 patients diagnosed with autoimmune pancreatitis (AIP), assigned to two groups based on serum immunoglobulin (Ig) G4 levels. Specifically, 148 patients were assigned to the abnormal group with serum IgG4 levels exceeding 2-fold the upper limit of the reference range, while 65 patients belonged to the normal group with serum IgG4 levels at or below this threshold. Through a comprehensive comparison of clinical characteristics and outcomes between these two groups, Zhou *et al*[1] identified higher serum IgG4 levels and age over 55 years as independent risk factors for disease relapse.

The significance of this large-sample study, considering the relative rarity of AIP, lies in its potential to contribute valuable insights to the management of patients with AIP. The findings suggest that monitoring serum IgG4 levels, particularly when exceeding 2-fold the upper limit of the reference range, can serve as a useful predictive indicator for

disease relapse. Furthermore, the identification of age over 55 years as an independent risk factor adds dimension to the prognostic considerations for AIP. The implications of these results are noteworthy, as they may guide clinicians in developing more targeted and effective management strategies for AIP patients. The study conducted by Zhou *et al*[1] provides a solid foundation for further discussions and investigations in the field of AIP, shedding light on potential paths for improved patient care and outcomes.

AIP represents a distinctive form of chronic pancreatitis triggered by aberrant autoimmune or inflammatory reactions. The disease encompasses two clinical subtypes, namely type 1 (histologically defined as lymphoplasmacytic sclerosing pancreatitis) and type 2 (histologically defined as idiopathic duct-centric pancreatitis). Despite sharing indistinguishable imaging manifestations and exhibiting a complete response to steroid treatments, these two subtypes display distinct clinical, histological, and prognostic features[2]. Notably, patients with AIP type 1 exhibit higher IgG4 seropositivity (60%-80%)[3-5] and a more elevated relapse rate (up to 60%)[4] compared to those with type 2, where IgG4 seropositivity is lower (approximately 20%)[4,5], and the relapse rate is correspondingly reduced (approximately 20%)[6,7]. Additionally, individuals with type 1 are, on average, two decades older than their type 2 counterparts[2].

One of the outstanding challenges in clinical practice is identifying reliable risk factors associated with the relapse of AIP type 1. Presently, the most pertinent factors include proximal bile duct involvement (*vs* no involvement), diffuse pancreatic enlargement (*vs* focal enlargement), and initial treatment with steroids (*vs* surgical resection)[8]. However, the role of elevated serum IgG4 levels and older age remains contentious, as discussed in this paper and other sources[8]. The primary contribution of this study is to underscore the significance of elevated serum IgG4 levels and older age in predicting relapse. However, it is crucial to interpret this contribution cautiously due to potential biases. Firstly, the cohort study included 189 patients with AIP type 1 and 24 with type 2, resulting in a proportion of type 2 patients of approximately 10%, consistent with an international multicenter study[9]. Consequently, most, if not all, AIP type 2 patients (with lower IgG4 seropositivity and lower relapse rates) were assigned

to the normal group, possibly inflating the association of higher serum IgG4 levels with relapse. Similarly, the abnormal group mostly comprised AIP type 1 patients with older age (as indicated in the study, male patients in the abnormal group were older than their normal group counterparts) and higher IgG4 seropositivity, potentially exaggerating the association of older age with relapse. Secondly, the authors did not provide sufficient details regarding AIP diagnosis, such as the ratio of definitive *vs* probable cases and the proportion of biopsies. According to international consensus diagnostic criteria, biopsy is mandatory for AIP type 2 but not for type 1[10]. However, in cases where histological evidence is unavailable or indeterminate, AIP type 2 may be misdiagnosed as definitive type 1[11], and type 1 may also be misdiagnosed as probable type 2, particularly in cases with normal or mildly elevated serum IgG4 levels. Lastly, in this retrospective study, a total of 308 consecutive patients were initially collected, but 95 patients (approximately one-third) were excluded for various reasons. As the exclusion was not random (*e.g.*, patients with no relapse were more likely to be excluded due to incomplete follow-up data), the impact of exclusion on relapse outcomes should be carefully considered.

In conclusion, the clinical research paper authored by Zhou *et al*[1] provides plausible, albeit not entirely compelling, evidence suggesting a predictive role of elevated serum IgG4 levels and advanced age in the relapse of AIP. These findings, while intriguing, warrant further validation through prospective, multi-center studies with larger sample sizes. The cornerstone of such investigations lies in ensuring a reliable diagnosis and accurate disease subtyping, a task heavily reliant on obtaining histological specimens. In this regard, endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) and biopsy (FNB) emerge as pivotal components of the diagnostic process. While EUS-FNA proves valuable in distinguishing between the two subtypes of AIP, particularly in seronegative cases[12], the overall performance of FNB surpasses that of FNA. A recent clinical research paper published in the EUS by Thomsen *et al*[13] sheds light on this aspect. Their examination of 852 consecutive pancreatic EUS-SharkCore FNB procedures, spanning both benign and malignant lesions, revealed the successful

acquisition of sufficient tissue cylinders for histological diagnosis in 93.4% (796/852) of cases. Despite immediate and late complications occurring in 5.4% and 4.7% of procedures, respectively, only 0.2% required intervention. Notably, among the FNB procedures from 15 patients with AIP (10 type 1 and 5 type 2), the study reported a sensitivity of 83.3%, a specificity of 99.5%, and an accuracy of 99.2%. Furthermore, EUS, especially ultrasound elastography, provides distinctive features that enhance the diagnosis of AIP, while concurrently aiding in its differentiation from pancreatic cancer[14,15]. Collectively, these studies underscore the potential of EUS-FNB as an optimal approach for diagnosing and subtyping AIP, offering a high level of efficacy and safety. This contributes to mitigating the introduction of various biases in future explorations of the disease.

REFERENCES

1 **Zhou GZ**, Zeng JQ, Wang L, Liu M, Meng K, Wang ZK, Zhang XL, Peng LH, Yan B, Pan F. Clinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study. *World J Gastroenterol* 2023; **29**: 5125-5137 [PMID: 37744294 DOI: 10.3748/wjg.v29.i35.5125]

2 **Li Y**, Song H, Meng X, Li R, Leung PSC, Gershwin ME, Zhang S, Sun S, Song J. Autoimmune pancreatitis type 2 (idiopathic duct-centric pancreatitis): A comprehensive review. *J Autoimmun* 2023; **140**: 103121 [PMID: 37826920 DOI: 10.1016/j.jaut.2023.103121]

3 **Masamune A**, Kikuta K, Hamada S, Tsuji I, Takeyama Y, Shimosegawa T, Okazaki K; Collaborators. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. *J Gastroenterol* 2020; **55**: 462-470 [PMID: 31872350 DOI: 10.1007/s00535-019-01658-7]

4 **Sah RP**, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, Pearson RK, Smyrk TC, Petersen BT, Topazian MD, Takahashi N, Farnell MB, Vege SS. Differences in clinical profile and relapse rate of type 1 *vs* type 2 autoimmune pancreatitis. *Gastroenterology* 2010; **139**: 140-8; quiz e12-3 [PMID: 20353791 DOI: 10.1053/j.gastro.2010.03.054]

5 **Kamisawa T**, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, Werner J, Bergmann F, Lerch MM, Mayerle J, Pickartz T, Lohr M, Schneider A, Frulloni L, Webster GJ, Reddy DN, Liao WC, Wang HP, Okazaki K, Shimosegawa T, Kloeppel G, Go VL. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. *Pancreas* 2011; **40**: 809-814 [PMID: 21747310 DOI: 10.1097/MPA.0b013e3182258a15]

6 **Tacelli M**, Celsa C, Magro B, Barresi L, Guastella S, Capurso G, Frulloni L, Cabibbo G, Cammà C. Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2019; **17**: 1061-1072.e8 [PMID: 30312787 DOI: 10.1016/j.cgh.2018.09.051]

7 **Nikolic S**, Lanzillotta M, Panic N, Brismar TB, Moro CF, Capurso G, Della Torre E, Löhr JM, Vujasinovic M. Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature. *United European Gastroenterol J* 2022; **10**: 496-506 [PMID: 35526270 DOI: 10.1002/ueg2.12237]

8 **Hart PA**, Zen Y, Chari ST. Recent Advances in Autoimmune Pancreatitis. *Gastroenterology* 2015; **149**: 39-51 [PMID: 25770706 DOI: 10.1053/j.gastro.2015.03.010]

9 **Hart PA**, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czakó L, Frulloni L, Go VL, Gress TM, Kim MH, Kawa S, Lee KT, Lerch MM, Liao WC, Löhr M, Okazaki K, Ryu JK, Schleinitz N, Shimizu K, Shimosegawa T, Soetikno R, Webster G, Yadav D, Zen Y, Chari ST. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. *Gut* 2013; **62**: 1771-1776 [PMID: 23232048 DOI: 10.1136/gutjnl-2012-303617]

10 **Shimosegawa T**, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, Kim MH, Klöppel G, Lerch MM, Löhr M, Notohara K, Okazaki K, Schneider A, Zhang L; International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. *Pancreas* 2011; **40**: 352-358 [PMID: 21412117 DOI: 10.1097/MPA.0b013e3182142fd2]

11 **Ikeura T**, Detlefsen S, Zamboni G, Manfredi R, Negrelli R, Amodio A, Vitali F, Gabbrielli A, Benini L, Klöppel G, Okazaki K, Vantini I, Frulloni L. Retrospective comparison between preoperative diagnosis by International Consensus Diagnostic Criteria and histological diagnosis in patients with focal autoimmune pancreatitis who underwent surgery with suspicion of cancer. *Pancreas* 2014; **43**: 698-703 [PMID: 24681878 DOI: 10.1097/MPA.0000000000000114]

12 **Ishikawa T**, Itoh A, Kawashima H, Ohno E, Matsubara H, Itoh Y, Nakamura Y, Hiramatsu T, Nakamura M, Miyahara R, Ohmiya N, Goto H, Hirooka Y. Endoscopic ultrasound-guided fine needle aspiration in the differentiation of type 1 and type 2 autoimmune pancreatitis. *World J Gastroenterol* 2012; **18**: 3883-3888 [PMID: 22876041 DOI: 10.3748/wjg.v18.i29.3883]

13 **Thomsen MM**, Larsen MH, Di Caterino T, Hedegaard Jensen G, Mortensen MB, Detlefsen S. Accuracy and clinical outcomes of pancreatic EUS-guided fine-needle biopsy in a consecutive series of 852 specimens. *Endosc Ultrasound* 2022; **11**: 306-318 [PMID: 35708361 DOI: 10.4103/EUS-D-21-00180]

14 **Tacelli M**, Zaccari P, Petrone MC, Della Torre E, Lanzillotta M, Falconi M, Doglioni C, Capurso G, Arcidiacono PG. Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. *Endosc Ultrasound* 2022; **11**: 216-222 [PMID: 35142701 DOI: 10.4103/EUS-D-21-00111]

15 **Cui XW**, Li KN, Yi AJ, Wang B, Wei Q, Wu GG, Dietrich CF. Ultrasound elastography. *Endosc Ultrasound* 2022; **11**: 252-274 [PMID: 35532576 DOI: 10.4103/EUS-

90705_Auto_Edited.docx

ORIGINALITY REPORT